F. M. Berger

1.1k total citations
69 papers, 661 citations indexed

About

F. M. Berger is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, F. M. Berger has authored 69 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Organic Chemistry, 10 papers in Molecular Biology and 10 papers in Pharmacology. Recurrent topics in F. M. Berger's work include Neuroscience and Neuropharmacology Research (8 papers), Immune Response and Inflammation (5 papers) and Dementia and Cognitive Impairment Research (4 papers). F. M. Berger is often cited by papers focused on Neuroscience and Neuropharmacology Research (8 papers), Immune Response and Inflammation (5 papers) and Dementia and Cognitive Impairment Research (4 papers). F. M. Berger collaborates with scholars based in United States, Germany and France. F. M. Berger's co-authors include B. J. Ludwig, M. Kletzkin, S. Margolin, J. F. Douglas, Lutz Frölich, J. P. Rosselet, Charles D. Hendley, Pasquale Calabrese, Colette Chapuis‐Cellier and J.L. Touraine and has published in prestigious journals such as Nature, The Journal of Immunology and Hepatology.

In The Last Decade

F. M. Berger

66 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. M. Berger United States 15 128 96 89 85 61 69 661
John A. Labudde United States 9 63 0.5× 137 1.4× 79 0.9× 74 0.9× 46 0.8× 13 772
Eigill F. Hvidberg Denmark 17 165 1.3× 99 1.0× 128 1.4× 317 3.7× 33 0.5× 52 921
A. Doenicke Germany 14 68 0.5× 81 0.8× 74 0.8× 117 1.4× 15 0.2× 73 678
Stanley Slater United States 14 159 1.2× 130 1.4× 255 2.9× 176 2.1× 26 0.4× 31 1.0k
A.C.A. Glen United Kingdom 15 118 0.9× 213 2.2× 178 2.0× 49 0.6× 36 0.6× 31 883
Erik Bechgaard Denmark 18 114 0.9× 144 1.5× 125 1.4× 135 1.6× 53 0.9× 45 751
Richard I. H. Wang United States 14 95 0.7× 181 1.9× 154 1.7× 170 2.0× 26 0.4× 67 985
Jens Schou Denmark 15 45 0.4× 105 1.1× 103 1.2× 159 1.9× 35 0.6× 74 840
Marion E. Wolf United States 17 251 2.0× 211 2.2× 201 2.3× 79 0.9× 70 1.1× 60 814
Erik Jacobsen Denmark 19 58 0.5× 201 2.1× 105 1.2× 64 0.8× 53 0.9× 43 903

Countries citing papers authored by F. M. Berger

Since Specialization
Citations

This map shows the geographic impact of F. M. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. M. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. M. Berger more than expected).

Fields of papers citing papers by F. M. Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. M. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. M. Berger. The network helps show where F. M. Berger may publish in the future.

Co-authorship network of co-authors of F. M. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of F. M. Berger. A scholar is included among the top collaborators of F. M. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. M. Berger. F. M. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Battegay, Manuel, Keikawus Arastéh, Andreas Plettenberg, et al.. (2011). Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study. Clinical Therapeutics. 33(9). 1308–1320. 8 indexed citations
2.
Huang, Fenglei, Paul Scholl, David B. Huang, et al.. (2010). Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(7). 1061–1070. 2 indexed citations
3.
Häger, Klaus, Pasquale Calabrese, Lutz Frölich, Claus Göbel, & F. M. Berger. (2003). An Observational Clinical Study of the Efficacy and Tolerability of Donepezil in the Treatment of Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 15(4). 189–198. 16 indexed citations
4.
Hampel, Harald, et al.. (2002). Donepezil in very elderly Alzheimer patients: Improvements in cognition and quality of life. Results of the 2nd German post marketing surveillance study. European Neuropsychopharmacology. 12. 381–381. 1 indexed citations
5.
Frölich, Lutz, et al.. (2002). Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. Journal of the Neurological Sciences. 203-204. 137–139. 9 indexed citations
6.
Frölich, Lutz, et al.. (2000). Effect of donepezil on behavior and activities of daily living in clinical practice. Neurobiology of Aging. 21. 161–161. 2 indexed citations
7.
Berger, F. M., et al.. (1988). Characterization of cellular infiltrate and HLA-DR expression patterns in chronic hepatitis B-virus infection using fine-needle aspiration cytology.. PubMed. 20(4). 652–3. 1 indexed citations
8.
Berger, F. M.. (1980). Effect of antianxiety drugs on fear and stress. Systems Research and Behavioral Science. 25(4). 315–321. 9 indexed citations
9.
Jl, Touraine, et al.. (1978). [Generalized BCG infection in mixed and severe immunologic deficiency. Unfavorable outcome in spite of an attempted bone marrow transplant].. PubMed. 34(7). 639–48. 1 indexed citations
10.
Berger, F. M., et al.. (1971). Studies on the Mechanism of Protodyne-Induced Protection against Microbial Infections. Experimental Biology and Medicine. 138(2). 391–395. 2 indexed citations
11.
Berger, F. M., et al.. (1967). Selective Suppression of Penicillin Hypersensitivity by Certain Phenoxy Propanediols. Experimental Biology and Medicine. 124(1). 303–310. 5 indexed citations
12.
Berger, F. M., J. F. Douglas, B. J. Ludwig, & S. Margolin. (1963). Effect of Benzyl N-Benzyl Carbethoxyhydroxamate (W-398) on Experimental Atherosclerosis and Hypercholesteremia. Experimental Biology and Medicine. 114(2). 337–341. 5 indexed citations
13.
Berger, F. M., J. F. Douglas, M. Kletzkin, B. J. Ludwig, & S. Margolin. (1961). THE PHARMACOLOGICAL PROPERTIES OF 2-METHYL-2-SEC-BUTYL-1,3-PROPANEDIOL DICARBAMATE (MEBUTAMATE, W-583), A NEW CENTRALLY ACTING BLOOD PRESSURE LOWERING AGENT. Journal of Pharmacology and Experimental Therapeutics. 134(3). 356–365. 13 indexed citations
14.
Berger, F. M.. (1960). Nonnarcotic drugs for the relief of pain and their mechanism of action. New York Academy of Sciences eBooks. 1 indexed citations
15.
Berger, F. M., et al.. (1959). UNUSUAL MUSCLE RELAXANT AND ANALGESIC PROPERTIES OF N-ISOPROPYL-2-METHYL-2-PROPYL-1, 3-PROPANEDIOL DICARBAMATE (CARISOPRODOL). Journal of Pharmacology and Experimental Therapeutics. 127(1). 66–74. 7 indexed citations
16.
Berger, F. M., et al.. (1957). Meprobamate and Other Agents Used in Mental Disturbances. The American Journal of the Medical Sciences. 234(6). 732–732. 4 indexed citations
17.
Berger, F. M., et al.. (1956). CENTRAL DEPRESSANT AND ANTICONVULSANT ACTIVITY OF COMPOUNDS ISOMERIC WITH 2-METHYL-2-n-PROPYL-1 ,3-PROPANEDIOL DICARBAMATE (MILTOWN). Journal of Pharmacology and Experimental Therapeutics. 116(3). 337–342. 6 indexed citations
18.
Berger, F. M., et al.. (1954). The analeptic action of l-n-butylamino-3-p-toluidino-2-propanol (W181) in sleep or paralysis produced by certain central nervous system depressants.. PubMed. 112(4). 399–403.
19.
Berger, F. M.. (1952). CENTRAL DEPRESSANT AND ANTICONVULSANT PROPERTIES OF GLYCEROL ETHERS ISOMERIC WITH MEPHENESIN. Journal of Pharmacology and Experimental Therapeutics. 105(4). 450–457. 5 indexed citations
20.
Berger, F. M.. (1952). THE CENTRAL DEPRESSANT PROPERTIES OF o-TOLOXYPROPYL CARBAMATES. Journal of Pharmacology and Experimental Therapeutics. 104(4). 468–473. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Labudde Breakdown of academic impact, for papers by Eigill F. Hvidberg Breakdown of academic impact, for papers by A. Doenicke Breakdown of academic impact, for papers by Stanley Slater Breakdown of academic impact, for papers by A.C.A. Glen Breakdown of academic impact, for papers by Erik Bechgaard Breakdown of academic impact, for papers by Richard I. H. Wang Breakdown of academic impact, for papers by Jens Schou Breakdown of academic impact, for papers by Marion E. Wolf Breakdown of academic impact, for papers by Erik Jacobsen
Rankless by CCL
2026